April 29, 2021
April 29, 2021 | Illumina joins the Gates Foundation in a global pathogen genomics initiative, new money for immune profiling, and Benchling nets $200M for their cloud platform.
$375M: Fund for Growth-Stage Medtech, Digital Health
Endeavour Vision has closed Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices, and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies 21 of which have exited via an acquisition or IPO. The fund has already supported seven companies with investm
Press release content from Business Wire. The AP news staff was not involved in its creation.
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
March 12, 2021 GMT
BOSTON (BUSINESS WIRE) Mar 12, 2021
Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known as molecular glues) that hijack the body’s innate ability to degrade proteins. Through this approach, Monte Rosa aims to eradicate undruggable proteins that cause or drive the progression of genomically-defined diseases intractable to standard care, including cancer.
RTW Participates in $95 Million Financing Round in Monte Rosa Therapeutics
RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Monte Rosa Therapeutics, Inc. ( Monte Rosa ) on 12 March 2021 of its completion of a $95 million Series C financing round.
The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms.
Monte Rosa is a privately held preclinical-stage biotech company discovering and developing small molecule degraders (also known as molecular glues) to eliminate disease-causing proteins. Monte Rosa plans to use the proceeds from the financing round to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its pl
Is BDSI A Good Stock To Buy? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.